Continuous glucose monitor (CGM)-derived metrics are going to continue to guide clinical decisions on patients with diabetes, and may have the potential to be even more impactful on the future of type 2 diabetes patients than even advancements in medication, according to 2 separately presented pieces of data at the 85th Scientific Sessions of the American Diabetes Association held in Chicago recently.
In the first piece of data from Dexcom researchers, CGM metrics were taken from 2752 veterans who initiated Dexcom CGM between 2015 and 2020 and that data were merged with electronic health records data.1 The researchers then made associations between mortality and CGM metrics, including estimated blood glucose (eBG), time in range (TIR), time above range (TAR), coefficient of variation (CV), and glycemic risk index (GRI).
“After adjusting for mortality-related variables, higher eBG, TAR, GRI, and CV, and lower TIR from 6 months of LM CGM were significantly linked with mortality,” researchers wrote in that study, adding “CGM-derived metrics predict all-cause mortality in patients with diabetes, independent of HbA1c, underscoring their importance for risk stratification.”
In the second piece of data, Dexcom officials released data that supported a recently released State of Type 2 Report in the United States that stated many healthcare professionals believe that CGM will have the potential to be more impactful on the future of type 2 diabetes care than advancements in diabetes medications.2
Earlier this year, Dexcom announced the release of its first multiregional report, detailing access and attitudes of individuals diagnosed with type 2 diabetes and healthcare professionals across Europe and the Middle East. The latest State of Type 2 Report now builds on those initial findings with data collected in the United States. Topline takeaways included the fact that 59% of US healthcare providers reported believing that better access to CGM will be the most effective way to help people with type 2 diabetes manage their condition over the next decade, and that 96% of those surveyed support CGM as the standard of care.1
During the conference, Dexcom presented extensive clinical data that show the benefits of CGM for those living with type 2 diabetes as well as new outcomes from early Stelo users.
Researchers presented clinical data at the conference that continues to support the benefits of its technology for people with diabetes of all ages and stages. Most notably, several studies looking at CGM use for those with type 2 diabetes across various insulin therapies demonstrated benefits—adding to an already extensive body of evidence—from reduced mortality risk among insulin-using people2 to reduced diabetes-related distress and improved self-management3 among non–insulin-using people.
In a real-world observational study of individuals with type 2 diabetes not using insulin, Dexcom G7 use was associated with significantly reduced diabetes-related distress and increased adherence to healthy eating plans and exercise routines, supporting CGM as a powerful tool for behavior modification.4
References
- Okuno T, Macwan S, Norman GJ. Continuous glucose monitoring metrics predict all-cause mortality in patients with both type 1 and type 2 diabetes. Diabetes. 2025;74:Suppl 1.
- Dexcom. The future of type 2 diabetes care. Accessed July 1, 2025. https://provider.dexcom.com/future-type-2-diabetes-care
- Liu BC, Hanna K, Nemelekar P, et al. Benefits of Dexcom rtCGM compared with SMBG among people with T2D or less intensive therapies. Diabetes. 2025;74:Suppl 1.
- Crawford MA, Hicks C, Elkind-Hirsh K, et al. Real-world Dexcom CGM use in T2D NIT: reduced diabetes distress and improved self-care behaviors. Diabetes. 2025;74:Suppl 1.